Procter & Gamble will acquire supplement brand Thorne for $3.8 billion, CEO Shailesh Jejurikar said on CNBC's "Squawk on the Street." The acquisition, set for formal announcement Tuesday, represents a clear strategic pivot for P&G into higher-margin health and wellness products.
The purchase strengthens P&G's existing supplement portfolio, which already includes Metamucil, Align Probiotic and New Chapter vitamins. Thorne's premium positioning and science-backed products give P&G access to a valuable consumer demographic, complementing its broader healthcare division that encompasses Oral-B and Vicks. Thorne is a strong strategic fit capable of driving incremental growth within P&G's consumer health segment.
The health and wellness market continues to show strong growth, driven by increasing consumer focus on preventative care and personalized nutrition. The sector has attracted substantial investment, with companies like Unilever and Nestlé actively expanding their health offerings through acquisitions. P&G's $3.8 billion outlay signals conviction that Thorne can deliver strong returns by using P&G's distribution and marketing scale to expand its total addressable market.
The $3.8 billion valuation reflects Thorne's strong growth trajectory and P&G's need to diversify revenue streams. Expect P&G to articulate clear synergy targets in supply chain optimization, research and development, and cross-selling within its existing healthcare ecosystem. Investors will scrutinize the deal's accretion to P&G's earnings per share and its impact on the company's overall margin profile in the coming quarters.
